Waters Corporation (WAT) Analyst Ratings & Price Targets

Waters Corporation

WAT · NYSE

Analyst Consensus

Buy

17 analysts

$405

Current

—

Low

$446

Average

—

High

Average target implies +10.20% versus the current price.

Analyst Ratings Synthesis

Consensus is Buy across all 17 analysts, with a mean price target of $420. The supplied consensus does not report a low or high target, so the target spread cannot be measured, and it does not identify which analyst is most or least bullish. No named analyst or bank is credited with a rating or target revision during the past week, so the direction of revisions is unavailable rather than demonstrably positive or negative. The substantive disagreement visible in the evidence is operational: the company raised 2026 guidance and beat second-quarter earnings and revenue estimates, while reporting a $136 million GAAP loss and a $1.39 loss per share versus a profit a year earlier. Individual target dispersion is not provided.

Rating Actions

No individual rating actions have been captured for WATyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

BAIRD R W

BARCLAYS CAPITA

CITIGROUP

CO FORECST

DEUTSCHE BK SEC

EVERCORE ISI

JEFFERIES & CO.

JP MORGAN SECUR

KEYBANC CAP MKT

LEERINK PARTNRS

SANFORD BERNSTE

STIFEL NICOLAUS

TD COWEN

UBS

WOLFE RESEARCH

ZACKS RESEARCH

Symbol: WAT
Type: Stock
Sector: Industrials
Industry: Laboratory Analytical Instruments
Exchange: NYSE

Waters Corporation (NYSE: WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of ~16,000 colleagues turn scientific challenges into breakthroughs that improve lives worldwide.

Key Issues

Bullish view

Waters raised 2026 guidance, while second-quarter earnings and revenue exceeded estimates by 1.33% and 1.25%, suggesting the forward outlook remains stronger than the reported quarter.

Bearish view

The quarter included a $136 million net loss and a $1.39 GAAP loss per share, versus $147 million of net income and $2.47 EPS a year earlier, raising questions about earnings quality and near-term profitability.

Analyst Consensus

See all

Buy

17 analysts

$405

Current

—

Low

$446

Average

—

High

Average target implies +10.20% versus the current price.

Earnings History

BeatMissNo estimate

Waters Corporation

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers